#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	14102	16S	1529	1529	99.87	16S.l15.c17.ctg.1	2307	744.1	0	.	n	.	0	A69G	SNP	69	69	A	445	445	G	854	G,A	845,9	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	14102	16S	1529	1529	99.87	16S.l15.c17.ctg.1	2307	744.1	0	.	n	.	0	C1450T	SNP	1450	1450	C	1826	1826	T	908	T,C,G,A	895,11,1,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	14102	16S	1529	1529	99.87	16S.l15.c17.ctg.1	2307	744.1	1	SNP	n	C1184T	0	.	.	1184	1184	C	1560	1560	C	876	C,G,A	873,2,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	23866	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4044	736.1	0	.	n	.	0	G1337A	SNP	1337	1337	G	1831	1831	A	939	A,G	936,3	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	23866	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4044	736.1	0	.	n	.	0	T1971C	SNP	1971	1971	T	2465	2465	C	894	C,T	893,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	23866	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4044	736.1	1	SNP	n	A2045G	0	.	.	2045	2045	A	2539	2539	A	816	A,T	815,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	23866	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4044	736.1	1	SNP	n	C2597T	0	.	.	2597	2597	C	3091	3091	C	816	C,T,A	814,1,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	23866	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4044	736.1	0	HET	.	.	.	A306G,C	.	306	306	A	800	800	A	891	A,G,C	668,222,1	.	.
folP.WHO_G_01367c	folP.WHO_G_01367c	1	1	539	2172	folP	852	852	99.88	folP.l6.c30.ctg.1	2119	128.0	0	.	p	.	0	E151K	NONSYN	451	453	GAA	1126	1128	AAA	217;216;219	A,G;A;A	215,2;216;219	.	.
folP.WHO_G_01367c	folP.WHO_G_01367c	1	1	539	2172	folP	852	852	99.88	folP.l6.c30.ctg.1	2119	128.0	1	SNP	p	R228S	1	.	.	682	684	AGC	1357	1359	AGC	223;224;223	A,G;G,C;C,A	222,1;223,1;222,1	folP.WHO_G_01367c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4738	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3986	148.5	1	SNP	p	S91F	0	.	.	271	273	TCC	881	883	TCC	172;175;176	T;C,G;C	172;174,1;176	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4738	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3986	148.5	1	SNP	p	D95G	0	.	.	283	285	GAC	893	895	GAC	187;187;189	G;A;C	187;187;189	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4738	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3986	148.5	1	SNP	p	D95N	0	.	.	283	285	GAC	893	895	GAC	187;187;189	G;A;C	187;187;189	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	27	1978	mtrR	633	633	100.0	mtrR.l15.c30.ctg.1	1882	131.3	1	SNP	p	G45D	0	.	.	133	135	GGC	708	710	GGC	231;232;231	G;G,A;C	231;231,1;231	mtrR.WHO_X_01389:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	1086	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1462	92.6	0	.	n	.	0	A197.	DEL	197	197	A	827	827	A	197	A	197	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5032	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3642	172.4	1	SNP	p	D86N	0	.	.	256	258	GAC	848	850	GAC	245;247;246	G,T;A,G,C;C	244,1;245,1,1;246	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5032	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3642	172.4	1	SNP	p	S87I	0	.	.	259	261	AGT	851	853	AGT	245;247;249	A;G;T	245;247;249	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5032	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3642	172.4	1	SNP	p	S87R	0	.	.	259	261	AGT	851	853	AGT	245;247;249	A;G;T	245;247;249	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5032	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3642	172.4	1	SNP	p	S87W	0	.	.	259	261	AGT	851	853	AGT	245;247;249	A;G;T	245;247;249	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5032	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3642	172.4	1	SNP	p	S88P	0	.	.	262	264	TCC	854	856	TCC	250;250;251	T,C;C,A;C	249,1;249,1;251	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	3990	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3262	152.8	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1855	1857	GGC	222;219;217	G;G,A;C	222;218,1;217	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.9.001	penA.9.001	1	1	27	3734	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2804	166.1	1	SNP	p	A311V	0	.	.	931	933	GCA	1487	1489	GCA	236;236;235	G;C;A	236;236;235	penA.9.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3734	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2804	166.1	1	SNP	p	I312M	0	.	.	934	936	ATC	1490	1492	ATC	234;233;230	A,T;T;C,A	233,1;233;229,1	penA.9.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3734	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2804	166.1	1	SNP	p	V316P	0	.	.	946	948	GTG	1502	1504	GTG	244;241;239	G;T;G	244;241;239	penA.9.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3734	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2804	166.1	1	SNP	p	V316T	0	.	.	946	948	GTG	1502	1504	GTG	244;241;239	G;T;G	244;241;239	penA.9.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3734	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2804	166.1	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2006	2008	ACC	202;204;204	A;C;C	202;204;204	penA.9.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3734	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2804	166.1	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2060	2062	GCG	193;190;189	G;C;G	193;190;189	penA.9.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3734	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2804	166.1	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2060	2062	GCG	193;190;189	G;C;G	193;190;189	penA.9.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3734	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2804	166.1	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2183	2185	GGC	185;186;185	G,A;G,C;C,A	184,1;185,1;184,1	penA.9.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3734	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2804	166.1	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2192	2194	GGC	188;188;190	G;G,A,C;C,A	188;186,1,1;189,1	penA.9.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3734	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2804	166.1	1	SNP	p	L552S	0	.	.	1654	1656	CTG	2210	2212	CTG	198;200;199	C;T,C,G;G	198;198,1,1;199	penA.9.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5210	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3625	179.6	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1918	1920	CCG	204;204;204	C;C;G	204;204;204	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2314	porA	1146	1146	99.65	porA.l6.c17.ctg.1	2229	129.3	0	.	p	.	0	M83fs	FSHIFT	247	247	A	798	798	C	191	C	191	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	300	porB1a	984	112	91.96	porB1a.l15.c17.ctg.2	199	51.5	0	.	p	.	0	M18T	NONSYN	52	54	ATG	133	135	ACG	61;58;58	A;C;G	61;58;58	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	300	porB1a	984	112	91.96	porB1a.l15.c17.ctg.2	199	51.5	0	.	p	.	0	E32Q	NONSYN	94	96	GAA	175	177	CAA	17;15;11	C;A;A	17;15;11	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	300	porB1a	984	112	91.96	porB1a.l15.c17.ctg.2	199	51.5	0	.	p	.	0	S34Y	NONSYN	100	102	TCC	181	183	TAC	4;2;1	T;A;C	4;2;1	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	300	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	300	29.5	0	.	p	.	0	V258L	NONSYN	772	774	GTA	14	16	TTA	25;26;28	T;T;A	25;26;28	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	300	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	300	29.5	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	59	61	CAT	61;61;61	C;A;T	61;61;61	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	300	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	300	29.5	0	.	p	.	0	D274S	NONSYN	820	822	GAT	62	64	AGT	61;61;61	A;G;T	61;61;61	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	300	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	300	29.5	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	71	73	TAC	61;61;61	T;A;C	61;61;61	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	300	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	300	29.5	0	.	p	.	0	R307A	NONSYN	919	921	AGA	161	163	GCA	1;1;1	G;C;A	1;1;1	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	300	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	300	29.5	0	.	p	.	0	T311A	NONSYN	931	933	ACA	173	175	GCA	1;1;1	G;C;A	1;1;1	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	300	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	300	29.5	0	.	p	.	0	E312D	NONSYN	934	936	GAA	176	178	GAC	2;2;2	G;A;C	2;2;2	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	300	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	300	29.5	0	.	p	.	0	F314I	NONSYN	940	942	TTC	182	184	ATC	2;2;2	A;T;C	2;2;2	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	300	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	300	29.5	0	.	p	.	0	A316S	NONSYN	946	948	GCG	188	190	TCG	2;2;2	T;C;G	2;2;2	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	300	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	300	29.5	0	.	p	.	0	V318A	NONSYN	952	954	GTC	194	196	GCC	2;2;2	G;C;C	2;2;2	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	300	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	300	29.5	0	.	p	.	0	G319S	NONSYN	955	957	GGC	197	199	AGC	2;2;2	A;G;C	2;2;2	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	300	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	300	29.5	0	.	p	.	0	G320A	NONSYN	958	960	GGT	200	202	GCC	2;2;2	G;C;C	2;2;2	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	300	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	300	29.5	0	.	p	.	0	G322V	NONSYN	964	966	GGT	206	208	GTT	2;2;2	G;T;T	2;2;2	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2922	porB1b	1047	1047	99.24	porB1b.l6.c17.ctg.1	2063	176.7	0	.	p	.	0	N38E	NONSYN	112	114	AAT	722	724	GAA	253;254;255	G;A,C;A,G	253;253,1;254,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2922	porB1b	1047	1047	99.24	porB1b.l6.c17.ctg.1	2063	176.7	0	.	p	.	0	N134D	NONSYN	400	402	AAT	1010	1012	GAT	263;260;262	G,A;A;T	262,1;260;262	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2922	porB1b	1047	1047	99.24	porB1b.l6.c17.ctg.1	2063	176.7	0	.	p	.	0	P175S	NONSYN	523	525	CCA	1133	1135	TCA	229;230;228	T;C;A	229;230;228	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2922	porB1b	1047	1047	99.24	porB1b.l6.c17.ctg.1	2063	176.7	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1262	1264	GTC	235;232;229	G;T;C,G	235;232;228,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2922	porB1b	1047	1047	99.24	porB1b.l6.c17.ctg.1	2063	176.7	0	.	p	.	0	F222S	NONSYN	664	666	TTT	1274	1276	TCT	226;228;230	T;C,T;T	226;226,2;230	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2922	porB1b	1047	1047	99.24	porB1b.l6.c17.ctg.1	2063	176.7	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1592	1594	GCA	223;224;222	G;C,G;A,G	223;223,1;221,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2922	porB1b	1047	1047	99.24	porB1b.l6.c17.ctg.1	2063	176.7	1	SNP	p	G120K	1	.	.	358	360	AAG	968	970	AAG	249;253;253	A;A;G,A	249;253;252,1	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2922	porB1b	1047	1047	99.24	porB1b.l6.c17.ctg.1	2063	176.7	1	SNP	p	D121N	0	.	.	361	363	GAC	971	973	GAC	255;255;255	G;A;C	255;255;255	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2922	porB1b	1047	1047	99.24	porB1b.l6.c17.ctg.1	2063	176.7	1	SNP	p	A121D	1	.	.	361	363	GAC	971	973	GAC	255;255;255	G;A;C	255;255;255	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	539	9076	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	5450	208.1	1	SNP	p	H553N	1	H553N	NONSYN	1657	1659	CAT	2365	2367	AAT	273;272;272	A,C;A;T	272,1;272;272	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1276	rpsJ	312	312	100.0	rpsJ.l15.c17.ctg.1	1352	116.9	1	SNP	p	V57M	1	.	.	169	171	ATG	701	703	ATG	239;239;242	A;T,C;G	239;238,1;242	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
